Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Speed of cancer drug administration increased

  • Comment

Cancer patients can now get vital treatment in just five minutes instead of two hours after a new injection procedure is trialled.

Patients diagnosed with follicular non-Hodgkin lymphoma (NHL), previously had rituximab administered via an intravenous drip.

But the trial at Southampton General Hospital can now deliver a two-hour dose of drugs in around five minutes.

The procedure, which is just as effective, should now be rolled out nationwide.

Around 4,000 people, mainly in their 60s, are diagnosed with the disease in the UK every year and the majority of them will receive the drug, which targets and destroys specific proteins on the surface of cancerous cells, alongside chemotherapy to help eliminate all signs of the lymphoma and induce remission.

At the moment, most sufferers receive both treatments via a drip in a four-hour session once every three weeks.

When the six-month course of chemotherapy ends, patients often require a further two years of rituximab given over two hours once every eight weeks.

Results of the international study showed that giving the drug by a quick injection under the skin was as safe and effective as the conventional intravenous treatment.

Dr Andrew Davies, a consultant in medical oncology at the hospital who led the study, said: “This is a new formulation of a drug we are very familiar with and have been using for many years and the study demonstrates injection is equivalent to the intravenous drip method.

“In the near future, patients will be able to benefit from shorter, more convenient and potentially less complicated hospital visits, which will greatly reduce administration time for NHL patients and ease the capacity burden in busy chemotherapy day units.”

Dr Davies added: “There is a high degree of patient preference and satisfaction with this new formulation of rituximab in Southampton and we hope to see it rolled out nationwide very soon.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.